A few days after they announced that their
joint vaccine would undergo human clinical trials, Sanofi and GSK started the week with
additional news regarding the vaccine.
Oliver Bogillot, Sanofi’s French CEO,
announced that the vaccine's price would be €10 or less. Despite the announcement, he iterated the fact that the
final price hadn't been set yet.
Besides the price, the Sanofi plans to list
its active pharmaceutical ingredients (API) company publicly. The initial
public offering is scheduled to happen in the following months, and the new
business could be valued at up to €2billion.
It is the embodiment of a plan touted in
February, through which Sanofi will create a standalone company by reuniting
under the same roof its commercial and development activities and the power of
its six European production sites.
According to Sanofi, the move would balance
the industry's reliance on Asia for ingredients, which lately has been
disrupted by the pandemic. The drugmaker said that it is taking into
consideration a 2022 Euronext Paris listing. If it does it, the new API would
be the second-largest in the world after the Swiss Lonza.
Following the news, Sanofi stock price
gained 2%.
Sources:
marketwatch.com, finance.yahoo.com
